11:41 AM
 | 
Nov 21, 2018
 |  BioCentury  |  Finance

Alphamab's cancer cash

Alphamab Oncology to push several programs through the clinic with $100M A round

Alphamab Oncology spun out from Suzhou Alphamab Co. Ltd. and raised more than $100 million in a series A round to advance multiple cancer biologics through clinical testing.

Investors in the round, which closed on Nov. 17, include Advantech Capital, PAG, China Venture Capital Fund, OrbiMed Advisors, Heritage Provider Network and Janchor Partners.

Suzhou Alphamab launched in 2009 and has developed protein engineering and antibody screening technology platforms, as well as a pipeline of novel biologics and biosimilars for indications ranging from infectious...

Read the full 396 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >